Propentofylline: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Propentofylline": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 41: Line 41:
| molecular_weight = 306.360 g/mol
| molecular_weight = 306.360 g/mol
}}
}}
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Propentofylline''' ('''HWA 285''') is a [[xanthine]] derivative with purported [[neuroprotective]] effects.
'''Propentofylline''' ('''HWA 285''') is a [[xanthine]] derivative with purported [[neuroprotective]] effects.



Latest revision as of 17:01, 20 August 2015

Propentofylline
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H22N4O3
Molar mass306.360 g/mol
  (verify)

WikiDoc Resources for Propentofylline

Articles

Most recent articles on Propentofylline

Most cited articles on Propentofylline

Review articles on Propentofylline

Articles on Propentofylline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Propentofylline

Images of Propentofylline

Photos of Propentofylline

Podcasts & MP3s on Propentofylline

Videos on Propentofylline

Evidence Based Medicine

Cochrane Collaboration on Propentofylline

Bandolier on Propentofylline

TRIP on Propentofylline

Clinical Trials

Ongoing Trials on Propentofylline at Clinical Trials.gov

Trial results on Propentofylline

Clinical Trials on Propentofylline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Propentofylline

NICE Guidance on Propentofylline

NHS PRODIGY Guidance

FDA on Propentofylline

CDC on Propentofylline

Books

Books on Propentofylline

News

Propentofylline in the news

Be alerted to news on Propentofylline

News trends on Propentofylline

Commentary

Blogs on Propentofylline

Definitions

Definitions of Propentofylline

Patient Resources / Community

Patient resources on Propentofylline

Discussion groups on Propentofylline

Patient Handouts on Propentofylline

Directions to Hospitals Treating Propentofylline

Risk calculators and risk factors for Propentofylline

Healthcare Provider Resources

Symptoms of Propentofylline

Causes & Risk Factors for Propentofylline

Diagnostic studies for Propentofylline

Treatment of Propentofylline

Continuing Medical Education (CME)

CME Programs on Propentofylline

International

Propentofylline en Espanol

Propentofylline en Francais

Business

Propentofylline in the Marketplace

Patents on Propentofylline

Experimental / Informatics

List of terms related to Propentofylline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

Pharmacology

It is a phosphodiesterase inhibitor.[1]

It also acts as an adenosine reuptake inhibitor.[1][2][3]

Uses

It was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.[4][5]

Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[6][7]

Propentofylline is in use in veterinary medicine as a geriatric preparation for old dogs.

See also

References

  1. 1.0 1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  2. Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter |author-separator= ignored (help)
  3. Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
  4. Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  5. Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
  6. Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
  7. Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.

Template:Phosphodiesterase inhibitors